相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
Jeffrey A. Cohen et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
Jonathan Q. Tran et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-I-Phosphate Receptor Modulator
Jonathan Q. Tran et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
Jonathan Q. Tran et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2016)
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
分享论文
